A new oral SERD, elacestrant, has more recently been developed but is currently only approved in the United States and the European Union for use in patients with ESR1-mutated ER+/HER2- breast cancer with disease progression following at least one line of endocrine therapy [17, 18]. This evidence concerns the gene ERBB2 and breast carcinoma.